导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -7.92% | 3626/4773 |
| 近一周 | -3.47% | 4211/5462 |
| 近一月 | -9.80% | 4865/5421 |
| 近一季 | -5.38% | 1831/5209 |
| 近半年 | -12.18% | 3768/4920 |
| 近一年 | -12.36% | 3545/4366 |
| 近两年 | 63.24% | 1113/2954 |
| 近三年 | 10.41% | 1736/2253 |
| 成立以来 | 4.66% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.88% 3717/4961 |
11.75% 2300/5312 |
- - |
- - |
| 2025 | 13.47% 2641/4813 |
4.75% 887/3635 |
-2.17% 3321/4076 |
23.76% 1516/4524 |
-10.53% 4164/4813 |
| 2024 | 11.23% 1338/3463 |
-6.43% 2052/2808 |
-12.23% 2596/3014 |
19.69% 816/3129 |
13.16% 158/3463 |
| 2023 | -1.43% 511/2656 |
36.59% 49/2280 |
-9.07% 2032/2385 |
-15.67% 2231/2515 |
-5.89% 1541/2655 |
| 2022 | -26.69% 1423/2207 |
-22.15% 1687/1919 |
-2.62% 1784/2016 |
-14.82% 1154/2113 |
13.52% 101/2208 |
| 2021 | -0.63% 757/1822 |
-6.75% 1036/1255 |
12.17% 343/1330 |
-8.77% 1155/1466 |
4.14% 362/1822 |
| 2020 | - - |
- - |
- - |
-0.24% 1052/1164 |
-0.24% 1067/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 天弘中证计算机ETF VS. 长安沪深300非周期A(740101) |